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Résumé en
anglais
Glioma are the most common malignant tumors of the central nervous system and
remain associated with poor prognosis, despite the combination of chemotherapy
and radiotherapy. EGFR targeting represents an interesting strategy to treat
glioma. Indeed, a high level of endothelial growth factor receptors expression
(EGFR), involved in the malignancy of the tumor, has been observed in glioma. Our
strategy consisted in using EGFR siRNA entrapped into lipid nanocapsules (LNCs)
via cationic liposomes. In vitro analyses on U87MG human glioma cells were
performed to evaluate firstly the capacity of LNCs to efficiently deliver the siRNA
and secondly the effect of EGFR siRNA targeting on U87MG proliferation. Then, the
complement protein consumption was evaluated by CH50 assays to verify the
suitability of the siRNA LNCs for systemic administration. The EGFR siRNA LNCs
exhibited an adequate size lower than 150 nm as well as a neutral surface charge.
The IC50 profile together with the 63% of protein extinction demonstrated the
significant action of EGFR siRNA LNCs compared to scrambled LNCs. Dose and
time-dependent survival assays showed a decrease of U87MG growth evaluated at
38%. Finally, low complement consumption demonstrated the suitability of EGFR
siRNA LNCs for intravenous injection. In conclusion, EGFR siRNA LNCs
demonstrated their capacity to efficiently encapsulate and deliver siRNA into
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